Literature DB >> 19161562

Migraine in the triptan era: lessons from epidemiology, pathophysiology, and clinical science.

Marcelo E Bigal1, Michel Ferrari, Stephen D Silberstein, Richard B Lipton, Peter J Goadsby.   

Abstract

The triptan era has been a time of remarkable progress for migraine diagnosis and treatment. In this paper, we review some of the advances achieved in migraine science during this era focusing on 3 themes: lessons from clinical practice, lessons from epidemiology and lessons from pathophysiology. Science has shown that migraine is a disorder of the brain, and that the key events happen in the the trigeminal neuronal pathways, not on blood vessels. Clinical science has led to the observation that migraine sometimes progresses or remits. This in turn led to longitudinal epidemiologic studies focusing on factors that determine migraine prognosis. In addition, these studies raised questions about the mechanisms of migraine progression, including the role of allodynia, obesity, inflammation, and medications as determinants of progression. This in turn opens a new set of scientific questions about the neurobiologic determinants of migraine, as well as of its clinical course, and exciting opportunities to develop new therapies for this highly disabling brain disorder.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19161562     DOI: 10.1111/j.1526-4610.2008.01336.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  17 in total

Review 1.  Therapeutic antibodies against CGRP or its receptor.

Authors:  Marcelo E Bigal; Sarah Walter; Alan M Rapoport
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

Review 2.  Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.

Authors:  Marcelo E Bigal; Sarah Walter
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

3.  Recruitment, retention, and adherence in a randomized feasibility trial of mindfulness-based stress reduction for patients with migraine.

Authors:  Heather Law; Andrew Avins; Robert Stahl; Michelle Goodreau; Alice Jacobson; Sylvia Sudat; Alice Pressman
Journal:  Complement Ther Med       Date:  2020-11-04       Impact factor: 2.446

Review 4.  Triptans for the management of migraine.

Authors:  Mollie M Johnston; Alan M Rapoport
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

5.  Evaluation of Eating Attitude in Patients with Migraine.

Authors:  Kadir Demirci; Seden Demirci; Abdullah Akpinar; Arif Demirdaş; İnci Meltem Atay
Journal:  Noro Psikiyatr Ars       Date:  2015-12-01       Impact factor: 1.339

6.  Triptan-induced latent sensitization: a possible basis for medication overuse headache.

Authors:  Milena De Felice; Michael H Ossipov; Ruizhong Wang; Josephine Lai; Juliana Chichorro; Ian Meng; David W Dodick; Todd W Vanderah; Gregory Dussor; Frank Porreca
Journal:  Ann Neurol       Date:  2010-03       Impact factor: 10.422

Review 7.  Targeting CGRP: A New Era for Migraine Treatment.

Authors:  Stephanie Wrobel Goldberg; Stephen David Silberstein
Journal:  CNS Drugs       Date:  2015-06       Impact factor: 5.749

Review 8.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

9.  Interictal quantitative EEG in migraine: a blinded controlled study.

Authors:  Marte Helene Bjørk; Lars J Stovner; Morten Engstrøm; Marit Stjern; Knut Hagen; Trond Sand
Journal:  J Headache Pain       Date:  2009-08-25       Impact factor: 7.277

Review 10.  Animal Models of Chronic Migraine.

Authors:  Tse-Ming Chou; Shih-Pin Chen
Journal:  Curr Pain Headache Rep       Date:  2018-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.